Ocugen, Inc/$OCGN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Ocugen, Inc

Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").

Ticker

$OCGN
Primary listing

Industry

Biotechnology

Employees

95

ISIN

US67577C1053

Ocugen, Inc Metrics

BasicAdvanced
$330M
-
-$0.21
4.24
-

What the Analysts think about Ocugen, Inc

Analyst ratings (Buy, Hold, Sell) for Ocugen, Inc stock.

Bulls say / Bears say

Ocugen's OCU400 Phase 3 clinical trial for retinitis pigmentosa is progressing well, with potential BLA/MAA filings by mid-2026, indicating significant advancement in their gene therapy pipeline. (Ocugen Press Release)
The company secured $30 million in debt financing in November 2024, bolstering its financial position to support ongoing research and development activities. (Ocugen Press Release)
Ocugen's OCU410ST received Rare Pediatric Disease Designation from the FDA for the treatment of Stargardt disease, potentially expediting its development and approval process. (Ocugen Press Release)
Ocugen reported a net loss of $0.05 per share for the first quarter of 2025, reflecting ongoing financial challenges. (Ocugen Press Release)
The company's revenue for 2024 was $4.05 million, a decrease of 32.82% compared to the previous year, indicating declining sales. (Stock Analysis)
Ocugen has a high short interest of 22.32% of outstanding shares, suggesting that a significant number of investors are betting against the stock. (Stock Analysis)
Data summarised monthly by Lightyear AI. Last updated on 10 Jul 2025.

Ocugen, Inc Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Ocugen, Inc Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $OCGN

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs